---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-25-000033"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T00:52:44.487416+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lexicon shareholders approve reverse stock split authorization (1:10-1:50) and increase equity plan share reserves

## Summary
- Shareholders approved reverse stock split at ratio 1-for-10 to 1-for-50, at board discretion before 2026 annual meeting.
- Equity incentive plan shares increased from 55M to 75M; Non-Employee Directors plan from 2M to 4M.
- Directors Raymond Debbane and Ivan H. Cheung elected with >205M and >226M votes for, respectively.
- Ernst & Young ratified as independent auditor for FY 2025.
- Advisory vote on executive compensation approved with 220.5M for, 7.9M against.

## SEC filing metadata
- accession: 0001062822-25-000033
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000033/0001062822-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000033/lxrx-20250602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-25-000033
- JSON: https://secwatch.observer/filing/0001062822-25-000033.json
- Plain text: https://secwatch.observer/filing/0001062822-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.